12:30 PM EST - Lobe Sciences Ltd : Announced it has updated its Corporate Slide Deck which among other initiatives, describes its plans for advancing the development of its psilocin analogues L-130 and L-131. Philip Young, CEO of Lobe Sciences stated, "We have made significant progress toward initiating our first human trials with our proprietary psilocin analog L-130 and pre clinical plans for L-131.' These updates can be found at our Company website https://www.lobesciences.com/corporate-profile/company-presentation/. Lobe Sciences Ltd
shares C.LOBE are trading unchanged at $0.07.
